Original from: Quanterix

Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets.

Under the terms of the amended merger agreement announced on April 29th, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash, in the aggregate, to holders of Akoya shares and other Akoya equity awards.

Masoud Toloue, PhD, Chief Executive Officer of Quanterix, said, “The acquisition of Akoya positions us to deliver comprehensive protein biomarker solutions that leverage signatures in blood and tissue, together providing a more holistic and predictive view of a patient’s disease.  This transaction extends our portfolio into new markets and is expected to expand our served addressable market from $1 billion to $5 billion.  We believe the combined business will benefit from significant scale, a strong balance sheet and an accelerated path to profitability by 2026.”

Source: Quanterix Completes Acquisition Of Akoya Biosciences, Creating The First Integrated Platform Capable Of Measuring Biomarkers Across The Blood And Tissue Continuum